Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 30
Summary
- Conditions
- Anaplastic Oligodendroglioma
- Anaplastic Astrocytoma
- Glioblastoma
- Anaplastic Ganglioglioma
- Anaplastic Pleomorphic Xanthoastrocytoma
- Pleomorphic Xanthoastrocytoma
- Angiocentric Glioma
- Oligodendroglioma, Childhood
- Astrocytoma
- Ganglioglioma
- Giant Cell Astrocytoma
- Papillary Glioneuronal Tumor
- Extraventricular Neurocytoma
- Central Neurocytoma
- Cerebellar Iponeurocytoma
- Chordoid Glioma of Third Ventricle
- Rosette-forming Glioneurona Tumor
- Pilocytic Astrocytoma
- Desmoplastic Infantile Astrocytoma and Ganglioglioma
- Dysplastic Gangliocytoma of Cerebrellum
- Gangliocytoma
- Diffuse Astrocytoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Younger than 1217 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02684058
- Collaborators
- Not Provided
- Investigators
- Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Get Well Soon